IMMUNE-MEDIATED NECROTIZING MYOPATHY
Clinical trials for IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Patients take the lead: rare myositis study puts your voice first
Knowledge-focused Recruiting nowThis study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are …
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Sponsor: Myositis International Health & Research Collaborative Alliance Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC